ACSL4 and neoplasm: In breast cancer and glioblastoma, CAFs disrupt the ferroptosis pathway by secreting miR-454-3p (targeting lipid metabolism enzyme ACSL4) and upregulating lncRNA DLEU1, promoting tumor survival (93, 94).